Zealand Pharma is a biotechnology company transforming metabolic health so millions of people can live without limits. With the opening of its new research hub at 35 CambridgePark Drive, Zealand Pharma is building a bridge between the science it has nurtured in Copenhagen for three decades and the extraordinary talent, ambition, and know-how found in Cambridge. The new site is an investment in both Zealand Pharma and the Massachusetts’s life sciences community that expands the company’s research beyond its core peptide expertise into hybrid modalities, built around automation and advanced modeling to shorten the cycle time from idea to clinic. The goal: medicines that give people not just longer lives, but more years in good health.
MassBio Member Spotlight: Zealand Pharma A/S
Location: Headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts
Therapeutic area(s): Metabolic health, Obesity, Chronic Inflammation,Congenital Hyperinsulinism, Short Bowel Syndrome
Leadership:
- Adam Steensberg, President and Chief Executive Officer
- Henriette Wennicke, Executive Vice President, Chief Financial Officer
- David Kendall, Executive Vice President, Chief Medical Officer
- Steven Johnson, Executive Vice President, Chief Development Officer
- Utpal Singh, Executive Vice President, Chief Scientific Officer
- Eric Cox, Executive Vice President, Chief Commercial Officer
Website: zealandpharma.com
